{"filings":[{"id":611316,"accession_number":"0001493152-26-025061","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-05-22T20:55:24+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Ensysce of delisting risk for equity shortfall","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.","Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.","Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.","Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":"2026-05-22","daily_digest_url":"/daily/2026-05-22","daily_digest_rank":2},{"id":471360,"accession_number":"0001493152-26-023810","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-05-15T20:20:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.","Cash and equivalents $0.7M at March 31, 2026; subsequent $2.0M convertible preferred financing closed April 7.","Achieved 50% of interim enrollment target in pivotal PF614-301 Phase 3 trial for moderate to severe pain.","IRB approval secured for Part 3 of PF614-MPAR-102; first peer-reviewed MPAR data published in Journal of Opioid Management.","Board initiated formal review of strategic alternatives, including partnerships and licensing opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":960999.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94943,"accession_number":"0001493152-26-015602","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.","Conversion price fixed at $0.55 per share; warrants with 100% coverage (18-month and 5-year terms) at $0.55 exercise price.","Amended Series B preferred stated value from $1,100 to $1,200 per share and issued 8,727,273 warrants.","CEO Lynn Kirkpatrick states financing reflects continued investor confidence in the company's analgesic programs.","Financing is part of up to $20M commitment available over 24 months from institutional investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94942,"accession_number":"0001493152-26-015139","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Curtis Rosebraugh resigns from Ensysce Biosciences board","event_type":"leadership","confidence":"high","bullets":["Resignation effective April 1, 2026; no reason given in notice.","Rosebraugh served on the Nominating and Corporate Governance Committee until resignation.","Resignation notice filed as Exhibit 17 to the 8-K.","No replacement announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107684,"accession_number":"0001493152-26-013622","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial","event_type":"earnings","confidence":"high","bullets":["Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.","R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.","Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.","FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.","USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107683,"accession_number":"0001493152-26-013314","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Lee Rauch resigns from Ensysce board over severance package dispute","event_type":"other_material","confidence":"high","bullets":["Lee Rauch resigned effective March 24, 2026, citing disagreement with board-approved severance packages.","Packages provide up to $205,475 in potential severance for CFO and three managers during strategic review.","CFO retention package increased from 6 to 9 months; packages contingent on non-retention in any strategic deal.","Board approved packages on March 27, 2026; Rauch had previously expressed other disagreements.","Company continues evaluating strategic alternatives for its business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107682,"accession_number":"0001493152-26-012062","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Ensysce corrects scrivener's error in Series B Preferred Stock designation","event_type":"other","confidence":"high","bullets":["Filed Certificate of Correction on March 18, 2026 to fix a scrivener's error in the Series B Preferred Stock designation.","Correction is to the Certificate of Designation, which is part of the Certificate of Incorporation.","No change in the rights or terms of the Series B Preferred Stock as a result of the correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107681,"accession_number":"0001493152-26-008343","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Feb 25, 2026; bid price closed below $1 for 30 consecutive business days.","Company has 180 days, until August 24, 2026, to regain compliance by closing at $1 for 10 consecutive days.","If not compliant by Aug 24, Nasdaq may grant a second 180-day period if other listing standards met.","Company intends to monitor bid price and evaluate options; trading on Nasdaq continues under ENSC.","Failure to regain compliance could lead to delisting, impairing capital raising and market liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107680,"accession_number":"0001493152-26-000994","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ensysce shareholders approve share issuance to investor and incentive plan increase","event_type":"other_material","confidence":"high","bullets":["Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.","Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 121,457 to 721,457.","Class I directors William Chang and Lee Rauch reelected; Chang: 518,597 for, Rauch: 516,907 for.","Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124051,"accession_number":"0001493152-25-023933","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available","event_type":"other_material","confidence":"high","bullets":["Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.","Conversion price fixed at $2.50/share; 50% warrant coverage exercisable at same price for five years.","Proceeds to accelerate Phase 3 clinical development of PF614, a novel abuse-resistant analgesic.","Series B preferred pays 4% annual dividend (8% on triggering events); stated value $1,100 per share.","Net proceeds from the offerings estimated at ~$3.6 million for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124050,"accession_number":"0001493152-25-023492","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.","Cash totaled $1.7M as of Sept 30, 2025; completed convertible preferred stock offering in Nov 2025 for $4M gross, with up to $16M additional over 24 months.","Initiated pivotal Phase 3 trial (PF614-301) for PF614 in moderate to severe post-surgical pain in July 2025.","FDA supported PF614-MPAR development for overdose protection labeling and confirmed potential streamlined 505(b)(2) pathway.","R&D expenses increased to $3.0M from $1.7M YoY; grant revenue fell to $0.5M from $3.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":3184314.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140727,"accession_number":"0001641172-25-023500","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.","Net loss $1.7M in Q2 2025 vs $2.0M loss in Q2 2024; R&D expenses rose to $1.9M from $0.9M.","Federal grant revenue $1.4M in Q2 2025 vs $0.2M in Q2 2024, driven by MPAR study activity.","Initiated pivotal Phase 3 trial (PF614-301) for post-surgical pain; Rho, Inc. engaged as CRO.","Received $5.3M NIDA installment and U.S. patent allowance for OUD candidate PF9001."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2691210.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158466,"accession_number":"0001641172-25-013853","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Ensysce Biosciences auditor changes to Baker Tilly after Moss Adams merger","event_type":"other_material","confidence":"high","bullets":["Moss Adams merged into Baker Tilly effective June 3, 2025; Baker Tilly appointed as successor auditor.","No disagreements or reportable events with Moss Adams during fiscal years 2024 and 2023.","Moss Adams' prior audit reports included a going concern explanatory paragraph.","Company had no consultations with Baker Tilly before appointment.","Moss Adams provided a letter agreeing with the statements in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158465,"accession_number":"0001641172-25-009949","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce Q1 net loss narrows to $1.9M; PF614-MPAR trial Part 1 completes, patent allowed for OUD candidate","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.","Cash $3.1M at March 31, 2025; subsequent warrant exercises raised $2.2M gross.","PF614-MPAR-102 Part 1 confirmed overdose protection at higher doses; Parts 2 & 3 enrollment underway.","U.S. patent allowed for PF9001 (OUD) covering composition of matter and method of use.","Federal grant funding increased to $1.3M from $0.3M, supporting MPAR and OUD programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":1319772.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158464,"accession_number":"0001641172-25-006009","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce raises $2.2M via warrant exercise inducement; issues new warrants for 1.26M shares","event_type":"other_material","confidence":"high","bullets":["Holders exercised 630,376 warrants at $3.24/share for cash; gross proceeds ~$2.2M before fees.","Company issued new unregistered warrants to purchase 1,260,752 shares at $1.90, split 18-month and 5-year terms.","Net proceeds ~$1.9M to fund TAAP and MPAR programs and working capital.","H.C. Wainwright acted as placement agent; received 7% cash fee and 44,126 agent warrants at $4.05.","New warrants include 4.99% beneficial ownership limitation (9.99% at holder election)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158463,"accession_number":"0001641172-25-002087","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ensysce corrects auditor consent to include omitted S-3 registration statements","event_type":"other","confidence":"high","bullets":["Original consent filed March 10, 2025 with Form 10-K omitted references to Registration Statements No. 333-275456 and No. 333-276537.","Revised consent dated April 1, 2025 is filed as Exhibit 23.1 to this 8-K.","No change to any previously reported financial results or disclosures in the 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176837,"accession_number":"0001641172-25-001751","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Ensysce Biosciences closes $1.1M registered direct offering and private placement of warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $1.1M from sale of 315,188 shares (or equivalents) at $3.49/share.","Concurrent private placement: Series A-5 warrants (18-month term) and Series A-6 warrants (5-year term), each exercisable at $3.24/share.","Net proceeds of ~$0.9M to fund TAAP and MPAR program development and working capital.","H.C. Wainwright acted as exclusive placement agent; placement agent warrants for 22,063 shares at $4.3625/share.","30-day lock-up on further equity issuance and insider sales; beneficial ownership limitation of 4.99% (or 9.99%) on warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176836,"accession_number":"0001493152-25-009695","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner","event_type":"earnings","confidence":"high","bullets":["Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.","Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.","PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.","FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176835,"accession_number":"0001493152-25-004880","cik":1716947,"company_name":"Ensysce Biosciences, Inc.","ticker":"ENSC","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal","event_type":"other_material","confidence":"high","bullets":["Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.","Ensysce issues 1% of outstanding shares as restricted stock vesting in thirds based on project milestones.","Development costs compensated with 50% restricted stock and 50% freely tradeable shares at 1.2x actual cost.","15-year term with IP created related to Ensysce's products owned exclusively by Ensysce.","Share price fixed using trailing five-day closing price; no future variable pricing permitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}